Romosozumab: a novel bone anabolic treatment option for osteoporosis?

Wien Med Wochenschr · 2020 · PMC7098919 · PMID 31858345

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Between-group differences of non-vertebral fracture risk (19%) and hip fracture risk (38%) did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.